The Next Chapter for GLP-1s: Why Once-Weekly Oral Dosing Could Change the Conversation
The GLP-1 landscape continues to evolve, and the next stage of innovation may focus increasingly on how medicines fit into people’s lives, as well as what they can achieve clinically.
A recent agreement between Novo Nordisk and Hengrui Pharma provides an example of this direction. On 29 September 2026, the companies announced an exclusive licensing agreement for HRS-1596, an investigational GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing.
The important caveat is that HRS-1596 remains at an early stage. Hengrui has received approval in China to initiate Phase I clinical trials, but the medicine has not yet generated human clinical efficacy or safety data. Its once-weekly oral administration is a development proposition rather than an established clinical outcome, and that distinction matters when considering what this announcement tells us about the future of GLP-1 treatment.
From GLP-1 Efficacy to Treatment Experience
The success of GLP-1 medicines has created a highly competitive therapeutic landscape, but competition is no longer simply about developing another medicine within the same category. Companies are exploring different mechanisms, combinations, formulations and routes of administration, with convenience becoming an increasingly visible part of the conversation.
HRS-1596 is notable because it combines two propositions: a GLP-1/GIP dual agonist and the potential for once-weekly oral administration. Hengrui and Novo describe the candidate as being designed to support weight reduction and glycemic control through mechanisms including appetite suppression, stimulation of insulin secretion and improved insulin sensitivity. Whether these intended effects translate into meaningful clinical outcomes remains to be established through clinical development.
The potential dosing schedule is therefore an important part of the development proposition. Existing oral GLP-1 treatment options include daily administration, while some injectable GLP-1 and related therapies are administered weekly. HRS-1596 could potentially combine oral administration with a once-weekly schedule, which, if achieved, would reduce dosing frequency compared with some current daily oral offerings
That does not mean a once-weekly oral treatment will automatically be preferred. Clinical effectiveness, safety, tolerability, suitability for individual Patients, administration requirements, access and cost will all remain important considerations. It does suggest, however, that dosing and treatment experience could become increasingly relevant dimensions of differentiation as the market develops.
What Will Matter to HCPs?
As new treatment propositions enter development, understanding how healthcare professionals interpret those propositions becomes increasingly important.
A company can understand the pharmacology of a medicine, its clinical trial results and its intended positioning, but that does not necessarily show how the treatment will be understood in clinical practice. HCPs bring their experience of existing therapies, Patient needs, treatment pathways and practical considerations to the way they assess a new option.
For an emerging therapy such as HRS-1596, this creates an opportunity to understand how the market responds to the proposition as evidence develops. The relevance of once-weekly oral administration, how it compares with existing expectations around injectable and oral treatments, and which Patient considerations on dosing frequency will all form part of that assessment.
These considerations become particularly important as the market moves from a period of rapid category creation into one of increasing differentiation.
Listening Alongside Clinical Development
The development journey for HRS-1596 has only just begun. Phase I studies will be an important next step in assessing its initial safety and tolerability and informing subsequent development, while later-stage studies will be needed to establish efficacy and further characterize the medicine.
Alongside this clinical journey, pharmaceutical companies can also benefit from understanding how HCPs are talking about emerging treatment concepts and which attributes they associate with value.
This does not replace clinical evidence, and it should not be used to make claims about a medicine before those claims are supported by appropriate evidence. Instead, HCP voice can provide context around the clinical and commercial considerations that teams are exploring, helping them understand how new propositions are being interpreted in the real world.
For companies operating in an increasingly crowded GLP-1 market, that distinction could become important. The challenge is not simply to develop another treatment, but to understand where its proposition may be perceived as differentiated and how that perception relates to the clinical evidence as it emerges.
The Next Stage of GLP-1 Competition
The Novo-Hengrui agreement is interesting beyond the value of the transaction itself. It is another indication of how pharmaceutical companies are looking for the next generation of differentiation within metabolic health.
HRS-1596 remains an investigational asset, and its potential should not be confused with established clinical evidence. Its development proposition does, however, illustrate how the definition of innovation in GLP-1s is expanding. Mechanism, efficacy, formulation, dosing frequency and treatment experience can all form part of the conversation as companies explore how to develop medicines that meet evolving needs.
For the industry, this makes understanding the voice of the HCP increasingly relevant. Clinical evidence will determine what a medicine can ultimately demonstrate, but understanding how HCPs interpret new treatment attributes can help companies understand the context in which that evidence will be received.
As the GLP-1 market enters its next phase, the question may become less about whether another GLP-1 can enter the market and more about what genuinely meaningful differentiation looks like to the people who prescribe, use and experience these medicines. That is where clinical development, market intelligence and the real-life voice of HCPs can increasingly come together.
References
- First oral GLP-1 treatment for weight management
- Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
- Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
- Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
- Novo to pay up to $2.6 billion to China’s Hengrui for rights to weight-loss pill
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population